References

1.      Annewieke W. van den Beld, Frank H. de Jong, et al. Measures of Bioavailable Serum Testosterone and Estradiol and Their Relationships with Muscle Strength, Bone Density, and Body Composition in Elderly Men¹   . J Clin Endocrinol Metab. Vol. 85, No. 9 3276-3282. 2000

2.      Bross R, Javanbakht M and Bhasin S. Anabolic Interventions for Aging-Associated Sarcopenia. Vol. 84, No. 10 3420-3430 1999.

3.      Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992 Oct;75(4):1092-8.

4.      Shalender B and Tenover JS. Age-Associated Sarcopenia—Issues in the Use of Testosterone as an Anabolic Agent in Older Men. 1997 Vol. 82, No. 6 1659-1660

5.      Urban RJ, Bodenbrug YH, et al.  Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995 Nov;269(5 Pt 1):E820-6.

6.      Snyder, P; The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992 Dec;16(12):991-7.

7.      Snyder P, Peachey H, Hannoush P, et al. Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age. J Clin Endocrinol Metab. Vol. 84, No. 6 1966-1972 1999.

8.      Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992 Dec;16(12):991-7.

9.      Sundeep Khosla, L. Joseph Melton, III, Elizabeth J. Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estrogen. . J Clin Endocrinol Metab. 1998 Vol. 83, No. 7 2266-2274

10.  Chute, G., Sex hormones and coronary artery disease. Am J Med. 1987 Nov;83(5):853-9.

11.  Khaw KT, Barrett-Connor E; Lower endogenous androgens predict central adiposity in men. Ann Epidemiol. 1992 Sep;2(5):675-82.

12.  Khaw KT, Barrett-Connor E; Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens. 1988 Apr;6(4):329-32..

13.  Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med. 1992 Oct;1(6):329-36.

14.  Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH; Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. 1997 Oct 15;146(8):609-17

15.  English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS; Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000 Jun;21(11):890-4.

16.  English KM, Steeds RP, Jones TH, Diver MJ, Channer KS; Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000 Oct 17;102(16):1906-11 

17.  Wu SZ, Weng XZ; Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl). 1993 Jun;106(6):415-8

18.  Webb CM, Adamson DL, de Zeigler D, Collins P; Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999 Feb 1;83(3):437-9, A9.

19.  Muller, M, Endogenous Sex Hormones and Cardiovascular Disease in Men; The Journal of Clinical Endocrinology & Metabolism 2003 Vol. 88, No. 11 5076-5086

20.  Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT.         Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005 May;90(5):2618-23.

21.  Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology. 2003 Feb;28(2):139-68.

22.  Moffat SD et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 27-JAN-2004; 62(2): 188-93.

23.  Gouras GK, Xu H, Gross RS, et al. Testosterone reduces neuronal secretion of Alzheimer’s β-amyloid peptides. Proc Natl Acad Sci USA 2000; 97: 1202–1205

24.  Papasozomenos SCh, Shanavas A. Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1140-5.

25.  Gillett MJ., Martins RN, Clarnette RM, Chubb SA, Bruce DG, Yeap BB; Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis. 2003 Aug;5(4):267-9.

26.  Tan RS, Pu SJ., A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male. 2003 Mar;6(1):13-7

27.  Hogervorst E, Combrinck M, et al. Testosterone and gonadotropin levels in men with dementia. Neuro Endocrinol Lett. 2003;24(3-4):203-8.

28.  Hogervorst E, Bandelow S, Combrinck M, Smith AD.; Low free testosterone is an independent risk factor for Alzheimer's disease. 2004 Nov-Dec;39(11-12):1633-9.

29.  Paoletti AM, et al; Low androgenization index in elderly women and elderly men with Alzheimer's disease. Neurology. 2004 Jan 27;62(2):301-3.

30.  Ramzi R. Hajjar, Fran E. Kaiser and John E. Morley.  Outcomes of Long-Term Testosterone Replacement in Older Hypogonadal Males: A Retrospective Analysis. J Clin Endocrinol Metab. 1997 Vol. 82, No. 11 3793-3796

31.  M Kwan, WJ Greenleaf, J Mann, L Crapo and JM Davidson. The nature of androgen action on male sexuality: a combined laboratory- self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983 Vol 57, 557-562,

32.  Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecenoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 1981;14:49-61

33.  O'Carroll R, Bancroft J Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Br J Psychiatry. 1984 Aug;145:146-51.

34.  Ebert T, Jockenhovel F, Morales A, etc. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol. 2005 Feb;47(2):137-46.

35.  Carani C, Zini D, Baldini A, et al. Effects of androgen treatment in impotent men with normal and low levels of free testosterone. Arch Sex Behav. 1990 Jun;19(3):223-34.

36.  Jain J;  Urol Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998 Feb;159(2):441-3.

37.  Cooper CS, Perry PJ,Sparks, et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998 Feb;159(2):441-3.

38.  Margolese HC. The male menopause and mood: testosterone decline and depression in the aging male--is there a link? J Geriatr Psychiatry Neurol. 2000 Summer;13(2):93-101

39.  Morley JE Testosterone replacement and the physiologic aspects of aging in men. Mayo Clin Proc. 2000 Jan;75 Suppl:S83-7

40.  Shehzad Basaria, Justin T. Wahlstrom and Adrian S. Dobs Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases. . J Clin Endocrinol Metab. 2001. Vol. 86, No. 11 5108-5117

41.  Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000 Mar;163(3):824-7.

42.  Asbell SO, Raimane KC, Montesano AT, Zeitzer KL, Asbell MD, Vijayakumar S; Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients. J Natl Med Assoc. 2000 Sep;92(9):445-9..

43.  Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring, N Engl J Med. 2004 Jan 29;350(5):482-92

44.  Carter HB,et al; Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate. 1995 Jul;27(1):25-31

45.  Conway, HJ. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. (Int J Androl. 1988 Aug;11(4):247-64

46.  Tauber U, Schroder K, Dusterberg B, Matthes H.Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone.Eur J Drug Metab Pharmacokinet. 1986 Apr-Jun;11(2):145-9.)

47.  Gries, et al. Down-Regulation Models and Modeling of Testosterone Production Induced by Recombinant Human Choriogonadotropin; Pharmacology and Experimental Therapeutics, April, 1999, pp 371-377

48.  Hayes F, :Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab. 2000 Sep;85(9):3027-35.

49.  Mauras N, Estrogen suppression in males: metabolic effects J Clin Endocrinol Metab. 2000 Jul;85(7):2370-7.

50.  Leder B,  Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels; J Clin Endocrinol Metab. 2004 Mar;89(3):1174-80.

51.  Vermeulen A. Declining androgens with age - an overview. Androgens and the ageing male. Eds. Oddens B. Vermeulen A. Parthenon Publishing. New York. 1996